Anti-CD112R/PVRIG (Hu) from Mouse (R12) – unconj.
incl. 19% VAT excl. Shipping cost
SKU DIA-R12 Specificity Species Reactivity Immunogen Host Species Isotype Clone Clonality (Mono-/Polyclonal) Application
Immunohistochemistry (IHC), Immunohistochemistry (Paraffin-embedded Sections), Western Blot
Conjugation Dilution Format
0.05% NaN3, 2% BSA, in PBS (pH 7.4), lyophilisate, purified antibody (from culture supernatant)
Product line / Topic Intended Use Temperature - Storage Temperature - Transport Search Code Manufacturer / Brand Uniprot_ID Gene_ID Alias
C7orf15, CD112 receptor, CD112R, Poliovirus receptor-related immunoglobulin domain-containing protein, PVRIG, Transmembrane protein PVRIG
- Datasheets and Downloads
Additional Product Information
Anti-CD112R antibody clone R12 validated for fluorescence multiplex immunohistochemistry
Anti-PVRIG/CD112R clone R12 has been developed for detection of CD112R in routine formalin-fixed paraffin-embedded tissue specimen (IHC FFPE). Clone R12 displays no background in epithelial cells and in non lymphoid cells and has been validated for sensitivity and specificity in different normal and tumor tissues. Clone R12 has been validated for use in bright field immunohistochemistry and for multicolor immunofluorescence (fluorescence multiplex IHC). Clone R12 is ideally suited for multiplexed immunohistochemistry studies of CD112R in human tissue specimen because of its inherent high signal to noise ratio.
CD112R, a member of poliovirus receptor–like proteins, is preferentially expressed on T-cells and inhibits T-cell receptor mediated signals. Blockade of the CD112R-CD112 interaction enhances T cell response. CD112, the ligand for CD112R, is widely expressed on tumor cells and on antigen-presenting cells. CD112R acts as a co-inhibitory receptor for T cells by its ability to compete with CD226 to bind to CD112. Blockage of the CD112R-CD112 interaction enhances human T cell response.
TIGIT and CD226 constitute a T cell co-signaling pathway in which CD226 and TIGIT, respectively, serve as costimulatory and co-inhibitory receptors for the ligands CD155 and CD112. This TIGIT signaling axis includes a complex receptor ligand system with the marker CD112R, which has become a promising target in cancer immuno-therapy.